Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  RaySearch Laboratories AB (publ)    RAY B   SE0000135485

RAYSEARCH LABORATORIES AB (PUBL) (RAY B)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

RaySearch Laboratories publ : and Eckert & Ziegler BEBIG Enter Into Partnership Regarding Brachytherapy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 11:47pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- RaySearch and Eckert & Ziegler BEBIG, a leading European supplier of brachytherapy products, have signed a partnership agreement. Both the RayStation® treatment planning system and the RayCare* oncology information system will be integrated* with the Eckert & Ziegler BEBIG brachytherapy systems (see also RaySearch Laboratories).

This will allow Eckert & Ziegler BEBIG to offer a complete brachytherapy solution, including treatment devices, treatment planning and oncology information management. The cooperation is in line with RaySearch's aim to support as many treatment systems and approaches as possible.

Brachytherapy is a radiation therapy technique in which a small radioactive implant is inserted into the patient's tissue, directly into the tumor or close to it. The implant may be temporary or permanent. Using implants makes it possible to deliver a higher dose of radiation to a smaller area than may possible with other forms of radiation therapy, thus minimizing damage to surrounding tissue and organs. Brachytherapy is most commonly used in treating prostate cancer but can be applied to many other areas, including cancers of the brain, eye, lung and skin.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler BEBIG, says: "We are very happy about the partnership with RaySearch, which promises a pathway to better integration of brachytherapy into modern radiation therapy workflows. Brachytherapy can significantly improve treatment outcome, either as a single treatment method or in combination with other therapies. Integration is key for future optimization, and this partnership is an important step forward."

Johan Lof, CEO of RaySearch, says: "It is exciting to enter into this new treatment area for RayStation and RayCare. Brachytherapy is a highly accurate technique, and the capabilities of our software will bring a new dimension to treatment. We have an excellent partner in Eckert & Ziegler BEBIG, a leading brachytherapy innovator with an excellent product portfolio, and I look forward to a successful collaboration."

Keywords for this news article include: Pharmaceuticals, Business, Radiotherapy, Brachytherapy, Radiation Therapy, Drugs and Therapies, Health and Medicine, RaySearch Laboratories.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

Stocks mentioned in the article
ChangeLast1st jan.
ECKERT & ZIEGLER BEBIG 1.70% 8.95 Delayed Quote.-0.57%
RAYSEARCH LABORATORIES AB (PUBL) -5.35% 123.9 Delayed Quote.-23.45%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RAYSEARCH LABORATORIES AB
08/23RAYSEARCH LABORATORIES PUBL : Interim report January 1- June 30, 2018
AQ
08/20RAYSEARCH LABORATORIES AB (PUBL) : half-yearly earnings release
08/09ONCOPEPTIDES : Anders Martin-Löf has been appointed as the new CFO of Oncopeptid..
AQ
07/27RAYSEARCH LABORATORIES PUBL : and Princess Margaret Cancer Centre enter strategi..
AQ
07/26RAYSEARCH LABORATORIES PUBL : New RayCare and RayStation releases on show at AAP..
AQ
07/18RAYSEARCH LABORATORIES PUBL : has been awarded a major tender for treatment plan..
AQ
07/13RAYSEARCH LABORATORIES PUBL : releases new version of the RayCare OIS
AQ
07/12RAYSEARCH LABORATORIES PUBL : and Eckert & Ziegler BEBIG Enter Into Partnership ..
AQ
07/12RAYSEARCH LABORATORIES PUBL : Researchers Submit Patent Application, "System and..
AQ
07/12RAYSEARCH LABORATORIES PUBL : The Ottawa Hospital Becomes the 500th Customer for..
AQ
More news
News from SeekingAlpha
08/23Raysearch Laboratories AB reports Q2 results 
Financials (SEK)
Sales 2018 642 M
EBIT 2018 159 M
Net income 2018 123 M
Debt 2018 1,67 M
Yield 2018 0,29%
P/E ratio 2018 36,60
P/E ratio 2019 26,73
EV / Sales 2018 5,27x
EV / Sales 2019 4,09x
Capitalization 3 381 M
Chart RAYSEARCH LABORATORIES AB (PUBL)
Duration : Period :
RaySearch Laboratories AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RAYSEARCH LABORATORIES AB
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 130  SEK
Spread / Average Target -0,69%
EPS Revisions
Managers
NameTitle
Johan Löf President, Chief Executive Officer & Director
Carl Filip Bergendal Chairman
Peter Thysell Chief Financial Officer
Kjell Eriksson Chief Science Officer
Hans Lennart Rudolf Wigzell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RAYSEARCH LABORATORIES AB (PUBL)-23.45%385
VEEVA SYSTEMS INC87.97%14 895
HEALTHEQUITY INC98.16%5 793
ATHENAHEALTH, INC2.68%5 618
OMNICELL, INC.44.33%2 749
ALLSCRIPTS HEALTHCARE SOLUTIONS INC-1.24%2 509